Edwards Lifesciences Corporation
—- Market cap
- —
- Debt
- —
- Cash
- −$2.94B
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · Mkt capMarket cap $54.56B · View financials
Decision snapshot: EW stock price vs CAH: inconclusive — current versus $59.37 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CAH's multiple
Implied fair value · at EW's multiple
Needs EW P/E.
Snapshot Sep 11, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
12 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 86% equity / 14% debt · EV / Revenue 0.23x · EV proxy / EBITDA proxy 16.42x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Edwards Lifesciences Corporation · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Cardinal Health, Inc. · implied price per share
Bear
$208.52
Base
$255.23
Bull
$319.63
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
ABBOTT LABORATORIES
EW vs ABT
JOHNSON & JOHNSON
EW vs JNJ
Medtronic plc
EW vs MDT
BOSTON SCIENTIFIC CORP
EW vs BSX
BAXTER INTERNATIONAL INC
EW vs BAX
DENTSPLY SIRONA Inc.
EW vs XRAY
MCKESSON CORP
EW vs MCK
AmerisourceBergen Corporation
EW vs ABC
Walgreens Boots Alliance, Inc.
EW vs WBA
CVS Health Corporation
EW vs CVS
HENRY SCHEIN INC
EW vs HSIC
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe EW can sustain double-digit growth and premium margins, then hold or accumulate on weakness because its fundamentals are materially stronger than CAH's despite the valuation premium; if not, the current price looks rich relative to the P/E, CAH-implied, and DCF estimates.
EW trades at $86.07 versus a P/E-based implied price of $64.42, implying 25.1% downside. The market is also valuing EW materially above CAH-implied range and DCF range, although it remains within its historical trading band.
Supporting Metrics